Logo image of CRXT

CLARUS THERAPEUTICS HOLDINGS (CRXT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRXT - US18271L1070 - Common Stock

0.099 USD
-0.06 (-36.94%)
Last: 8/30/2022, 8:05:42 PM
0.101 USD
+0 (+2.02%)
After Hours: 8/30/2022, 8:05:42 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CRXT. CRXT was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of CRXT is average, but there are quite some concerns on its profitability. CRXT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CRXT had negative earnings in the past year.
CRXT Yearly Net Income VS EBIT VS OCF VS FCFCRXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -66.68%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRXT Yearly ROA, ROE, ROICCRXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM -235.99%
PM (TTM) -193%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRXT Yearly Profit, Operating, Gross MarginsCRXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

CRXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRXT has about the same amount of shares outstanding.
Compared to 1 year ago, CRXT has an improved debt to assets ratio.
CRXT Yearly Shares OutstandingCRXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 5M 10M 15M 20M
CRXT Yearly Total Debt VS Total AssetsCRXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -11.36, we must say that CRXT is in the distress zone and has some risk of bankruptcy.
CRXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.36
ROIC/WACCN/A
WACC6.15%
CRXT Yearly LT Debt VS Equity VS FCFCRXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M -50M -100M

2.3 Liquidity

CRXT has a Current Ratio of 0.79. This is a bad value and indicates that CRXT is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.52 indicates that CRXT may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.52
CRXT Yearly Current Assets VS Current LiabilitesCRXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

CRXT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.
Looking at the last year, CRXT shows a very strong growth in Revenue. The Revenue has grown by 39.87%.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.34%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.73%

3.2 Future

Based on estimates for the next years, CRXT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.39% on average per year.
The Revenue is expected to grow by 57.00% on average over the next years. This is a very strong growth
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%

3.3 Evolution

CRXT Yearly Revenue VS EstimatesCRXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CRXT Yearly EPS VS EstimatesCRXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CRXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRXT Price Earnings VS Forward Price EarningsCRXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRXT Per share dataCRXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

CRXT's earnings are expected to grow with 25.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.54%
EPS Next 3Y25.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARUS THERAPEUTICS HOLDINGS

NASDAQ:CRXT (8/30/2022, 8:05:42 PM)

After market: 0.101 +0 (+2.02%)

0.099

-0.06 (-36.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-18 2022-08-18/amc
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner Change0%
Ins Owners9.87%
Ins Owner Change0%
Market Cap5.15M
Revenue(TTM)16.91M
Net Income(TTM)-32.63M
Analysts77.78
Price Target3.06 (2990.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.33
BVpS-0.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -66.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -235.99%
PM (TTM) -193%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.52
Altman-Z -11.36
F-Score3
WACC6.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.34%
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-20.73%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

CLARUS THERAPEUTICS HOLDINGS / CRXT FAQ

What is the fundamental rating for CRXT stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRXT.


What is the valuation status of CLARUS THERAPEUTICS HOLDINGS (CRXT) stock?

ChartMill assigns a valuation rating of 0 / 10 to CLARUS THERAPEUTICS HOLDINGS (CRXT). This can be considered as Overvalued.


Can you provide the profitability details for CLARUS THERAPEUTICS HOLDINGS?

CLARUS THERAPEUTICS HOLDINGS (CRXT) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CRXT stock?

The Earnings per Share (EPS) of CLARUS THERAPEUTICS HOLDINGS (CRXT) is expected to grow by 87.39% in the next year.